Annual SG&A
$11.36 M
-$2.17 M-16.05%
31 December 2023
Summary:
Akari Therapeutics annual selling, general & administrative expenses is currently $11.36 million, with the most recent change of -$2.17 million (-16.05%) on 31 December 2023. During the last 3 years, it has risen by +$2.20 million (+23.96%). AKTX annual SG&A is now -16.05% below its all-time high of $13.53 million, reached on 31 December 2022.AKTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.71 M
-$532.00 K-23.74%
01 September 2024
Summary:
Akari Therapeutics quarterly selling, general & administrative expenses is currently $1.71 million, with the most recent change of -$532.00 thousand (-23.74%) on 01 September 2024. Over the past year, it has dropped by -$1.11 million (-39.42%). AKTX quarterly SG&A is now -54.94% below its all-time high of $3.79 million, reached on 31 December 2017.AKTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$944.55 M
-$243.48 M-34.73%
01 September 2024
Summary:
Akari Therapeutics TTM selling, general & administrative expenses is currently -$944.55 million, with the most recent change of -$243.48 million (-34.73%) on 01 September 2024. Over the past year, it has dropped by -$953.33 million (-10864.14%). AKTX TTM SG&A is now -8128.46% below its all-time high of $12.82 million, reached on 31 March 2018.AKTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.1% | -39.4% | -10000.0% |
| 3 y3 years | +24.0% | -9.8% | -10000.0% |
| 5 y5 years | -2.9% | +26.2% | -10000.0% |
AKTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -16.1% | +40.5% | -53.9% | at low | -328.5% | at low |
| 5 y | 5 years | -16.1% | +40.5% | -53.9% | +26.2% | -328.5% | at low |
| alltime | all time | -16.1% | +3646.6% | -54.9% | +5813.5% | -8128.5% | at low |
Akari Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.71 M(-23.7%) | $10.24 M(-9.8%) |
| June 2024 | - | $2.24 M(-39.6%) | $11.35 M(-7.0%) |
| Mar 2024 | - | $3.71 M(+43.7%) | $12.20 M(+7.5%) |
| Dec 2023 | $11.36 M(-16.0%) | $2.58 M(-8.5%) | $11.36 M(+29.4%) |
| Sept 2023 | - | $2.82 M(-8.7%) | $8.78 M(+47.4%) |
| June 2023 | - | $3.09 M(+8.0%) | $5.95 M(+2.2%) |
| Mar 2023 | - | $2.86 M(-3.4%) | $5.83 M(-41.6%) |
| Dec 2022 | $13.53 M(+67.4%) | - | - |
| June 2022 | - | $2.96 M(-4.5%) | $9.98 M(+8.9%) |
| Mar 2022 | - | $3.10 M(+53.6%) | $9.17 M(+13.4%) |
| Dec 2021 | $8.08 M(-11.8%) | $2.02 M(+6.7%) | $8.08 M(-2.6%) |
| Sept 2021 | - | $1.89 M(-11.8%) | $8.29 M(+0.7%) |
| June 2021 | - | $2.15 M(+6.3%) | $8.24 M(-8.3%) |
| Mar 2021 | - | $2.02 M(-9.7%) | $8.99 M(-1.9%) |
| Dec 2020 | $9.16 M(+11.4%) | $2.24 M(+21.5%) | $9.16 M(+1.2%) |
| Sept 2020 | - | $1.84 M(-36.4%) | $9.05 M(+5.7%) |
| June 2020 | - | $2.89 M(+31.7%) | $8.57 M(+5.6%) |
| Mar 2020 | - | $2.19 M(+3.3%) | $8.11 M(-1.4%) |
| Dec 2019 | $8.22 M(-29.7%) | $2.12 M(+56.9%) | $8.22 M(-11.1%) |
| Sept 2019 | - | $1.35 M(-44.5%) | $9.25 M(-10.0%) |
| June 2019 | - | $2.44 M(+5.7%) | $10.28 M(-3.9%) |
| Mar 2019 | - | $2.31 M(-26.8%) | $10.70 M(-8.5%) |
| Dec 2018 | $11.69 M | $3.15 M(+32.3%) | $11.69 M(-5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $2.38 M(-16.7%) | $12.33 M(+1.8%) |
| June 2018 | - | $2.86 M(-13.3%) | $12.11 M(-5.5%) |
| Mar 2018 | - | $3.30 M(-13.1%) | $12.82 M(+8.6%) |
| Dec 2017 | $11.80 M(+18.7%) | $3.79 M(+75.7%) | $11.80 M(+4.5%) |
| Sept 2017 | - | $2.16 M(-39.5%) | $11.29 M(-0.6%) |
| June 2017 | - | $3.57 M(+56.4%) | $11.36 M(+15.1%) |
| Mar 2017 | - | $2.28 M(-30.6%) | $9.87 M(-0.7%) |
| Dec 2016 | $9.94 M(+80.7%) | $3.28 M(+47.4%) | $9.94 M(+10.2%) |
| Sept 2016 | - | $2.23 M(+7.3%) | $9.02 M(-5.3%) |
| June 2016 | - | $2.08 M(-11.7%) | $9.52 M(+22.8%) |
| Mar 2016 | - | $2.35 M(-0.4%) | $7.75 M(+40.9%) |
| Dec 2015 | $5.50 M(+1715.3%) | $2.36 M(-13.5%) | $5.50 M(+73.6%) |
| Sept 2015 | - | $2.73 M(+778.5%) | $3.17 M(+540.5%) |
| June 2015 | - | $310.80 K(+211.7%) | $494.90 K(-49.2%) |
| Mar 2015 | - | $99.70 K(+245.0%) | $974.10 K(-50.2%) |
| Dec 2014 | $303.10 K(-87.0%) | $28.90 K(-47.9%) | $1.96 M(+1.5%) |
| Sept 2014 | - | $55.50 K(-93.0%) | $1.93 M(+3.0%) |
| June 2014 | - | $790.00 K(-27.1%) | $1.87 M(+72.9%) |
| Mar 2014 | - | $1.08 M | $1.08 M |
| Dec 2013 | $2.33 M(+6.7%) | - | - |
| Dec 2012 | $2.18 M(+55.3%) | - | - |
| Dec 2011 | $1.41 M(+158.0%) | - | - |
| Dec 2010 | $545.00 K | - | - |
FAQ
- What is Akari Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Akari Therapeutics?
- What is Akari Therapeutics annual SG&A year-on-year change?
- What is Akari Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Akari Therapeutics?
- What is Akari Therapeutics quarterly SG&A year-on-year change?
- What is Akari Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Akari Therapeutics?
- What is Akari Therapeutics TTM SG&A year-on-year change?
What is Akari Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of AKTX is $11.36 M
What is the all time high annual SG&A for Akari Therapeutics?
Akari Therapeutics all-time high annual selling, general & administrative expenses is $13.53 M
What is Akari Therapeutics annual SG&A year-on-year change?
Over the past year, AKTX annual selling, general & administrative expenses has changed by -$2.17 M (-16.05%)
What is Akari Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of AKTX is $1.71 M
What is the all time high quarterly SG&A for Akari Therapeutics?
Akari Therapeutics all-time high quarterly selling, general & administrative expenses is $3.79 M
What is Akari Therapeutics quarterly SG&A year-on-year change?
Over the past year, AKTX quarterly selling, general & administrative expenses has changed by -$1.11 M (-39.42%)
What is Akari Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of AKTX is -$944.55 M
What is the all time high TTM SG&A for Akari Therapeutics?
Akari Therapeutics all-time high TTM selling, general & administrative expenses is $12.82 M
What is Akari Therapeutics TTM SG&A year-on-year change?
Over the past year, AKTX TTM selling, general & administrative expenses has changed by -$953.33 M (-10864.14%)